<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656561</url>
  </required_header>
  <id_info>
    <org_study_id>ANX007-GA-01</org_study_id>
    <nct_id>NCT04656561</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy</brief_title>
  <acronym>ARCHER</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) - The ARCHER Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted in participants with geographic atrophy (GA) secondary to&#xD;
      age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of&#xD;
      ANX007 reduce GA lesion growth rate. The results will be used to guide further development of&#xD;
      ANX007 in participants with geographic atrophy. The total duration of participation is&#xD;
      expected to be approximately 19 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GA lesion growth rate</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change in GA lesion area as assessed by fundus autofluorescence (FAF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>Number of participants with TEAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>Change from baseline in BCVA as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) test chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-luminance BCVA (LL-BCVA)</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>Change from baseline in LL-BCVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-luminance visual acuity deficit (LL-VD)</measure>
    <time_frame>Baseline to Month 18</time_frame>
    <description>Change from baseline in LL-VD</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>ANX007 Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANX007 administered every month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX007 Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANX007 administered every other month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Group 3</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham injection administered every month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Group 4</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham injection administered every other month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX007</intervention_name>
    <description>Form: solution for injection; Route of Administration: IVT</description>
    <arm_group_label>ANX007 Group 1</arm_group_label>
    <arm_group_label>ANX007 Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham comparator</intervention_name>
    <description>Form and Route of Administration: pressure to mimic IVT injection</description>
    <arm_group_label>Sham Group 3</arm_group_label>
    <arm_group_label>Sham Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of geographic atrophy of the macula secondary to age-related macular&#xD;
             degeneration as determined by the Investigator and confirmed by the Central Reading&#xD;
             Center.&#xD;
&#xD;
          -  GA lesion must have the following characteristics as determined by the independent&#xD;
             Central Reading Center based on assessment of FAF imaging at screening:&#xD;
&#xD;
               1. Well-demarcated GA with a total area (baseline lesion size) ≥2.5 mm2 and ≤17.5&#xD;
                  mm2.&#xD;
&#xD;
               2. If GA is multifocal, at least 1 focal lesion must measure ≥1.25 mm2 with the&#xD;
                  overall aggregate area of GA as specified above.&#xD;
&#xD;
               3. Presence of hyper autofluorescence, any pattern, in the junctional zone of the&#xD;
                  GA. Absence of hyper autofluorescence (ie, pattern = none) is exclusionary.&#xD;
&#xD;
               4. The entire GA lesion must be completely visualized on the macula centered image&#xD;
                  and must be able to be imaged in its entirety and not contiguous with any&#xD;
                  peripapillary atrophy.&#xD;
&#xD;
          -  Normal luminance best corrected visual acuity (BCVA) of 24 to 83 letters, inclusive,&#xD;
             using Early Treatment Diabetic Retinopathy Study (ETDRS) charts (20/25 to 20/320&#xD;
             Snellen equivalent, inclusive).&#xD;
&#xD;
          -  A female patient is eligible if she is not pregnant or breastfeeding and is a woman of&#xD;
             non-childbearing potential or is using a contraceptive method that is highly&#xD;
             effective, with a failure rate of &lt;1% during the study intervention period and for at&#xD;
             least 30 days after the last dose of study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod&#xD;
             dystrophy, pathologic myopia, or toxic maculopathies (eg, plaquenil maculopathy) in&#xD;
             either eye.&#xD;
&#xD;
          -  Any evidence of choroidal neovascularization (CNV) in the study eye:&#xD;
&#xD;
               1. Any history of CNV of any cause based on medical history.&#xD;
&#xD;
               2. Evidence of prior or active CNV or related findings (eg, retinal pigment&#xD;
                  epithelial rips or tears) based on FAF, SD-OCT imaging, intravenous fluorescein&#xD;
                  angiography (IVFA) and color fundus photo as assessed by the Central Reading&#xD;
                  Center.&#xD;
&#xD;
          -  Spherical equivalent of -8.00 diopters (D) myopia or higher in the study eye.&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (IOP &gt;25 mmHg despite treatment with anti-&#xD;
             glaucoma medication) or history of neovascular glaucoma.&#xD;
&#xD;
          -  History of glaucoma filtration surgery, minimally-invasive glaucoma surgery involving&#xD;
             an implant, or vitrectomy surgery, or other procedure in the study eye that could&#xD;
             affect drug distribution and/or clearance.&#xD;
&#xD;
          -  Any current or prior ocular disease, other than geographic atrophy, that in the&#xD;
             opinion of the Investigator could interfere with the conduct of the study including,&#xD;
             but not limited to, insufficient pupil dilation, retinal or optic nerve disease, media&#xD;
             opacity, or aphakia in the study eye.&#xD;
&#xD;
          -  History of any prior IVT treatment for any indication in the study eye.&#xD;
&#xD;
          -  Any prior treatment for AMD in the study eye (eg, surgical, radiation,&#xD;
             thermotherapeutic, or laser intervention), except oral supplements or minerals.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Annexon, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>650-822-5500</phone>
    <email>clinicaltrials@annexonbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

